Levazeo 25 Tablet contains Levosulpiride 25 mg, a selective dopamine D2 receptor antagonist primarily used in the treatment of gastrointestinal disorders and certain psychiatric conditions. Levosulpiride exerts prokinetic and antiemetic effects by enhancing gastric motility and modulating dopaminergic pathways in the central nervous system. It is commonly prescribed for functional dyspepsia, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) with predominant symptoms of nausea, vomiting, bloating, and abdominal discomfort. Additionally, Levazeo 25 is utilized in managing psychiatric disorders such as depression and schizophrenia due to its antipsychotic and mood-stabilizing properties. The recommended dosage varies depending on the indication and patient-specific factors, but typically ranges from 25 mg to 75 mg daily, administered orally. Caution is advised in patients with a history of hypersensitivity to sulpiride or related compounds, and it should be used cautiously in individuals with renal or hepatic impairment. Common adverse effects may include drowsiness, dizziness, dry mouth, and extrapyramidal symptoms, which necessitate monitoring during therapy. Levazeo 25 should be used under medical supervision, ensuring appropriate evaluation of therapeutic benefits against potential risks.